Background Olanzapine, neurokinin-1-receptor-antagonists (NK-1-RA), and thalidomide added to palonosetron + dexamethasone (PALO-DEX) have been evaluated in separate studies as prophylaxis for chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). We conducted a Bayesian network meta-analysis to compare the prophylactic efficacy of these agents in combination with PALO-DEX. Methods PubMed, Medline/Ovid, Embase, and Clinicaltrials.gov were searched from inception through 22 Mar 2018. Study quality was assessed using the Cochrane methodology. A Bayesian network meta-analysis using random-effects models was used to asses complete response (CR) and rate of no nausea (RNN) in acute, delayed, and overall phases and were expressed as odds ratios (OR) and 95% credible interval (95% CrI). Ranking probabilities of treatments were calculated using the surface under the cumulative ranking curve (SUCRA) to identify the probability of a given treatment as the best option against the worst option.
Introduction
Among the most severe consequences of chemotherapy are the acute and delayed phases of nausea and vomiting [1] . They impair quality of life, prolong hospitalization, and may lead to reductions in or interruption of chemotherapy. The 1991 approval of the serotonin receptor antagonist (5-HT 3 RA) ondansetron allowed an improved control of the acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV) with less side-effects compared with metoclopramide [1] . Since then, several additional prophylactic agents for CINV have been approved and antiemetic guidelines have been formulated [1] .
Palonosetron (PALO), a second-generation 5-HT 3 RA, has shown higher rates of CINV prevention, particularly for delayed emesis [2] [3] [4] [5] [6] . This has been linked to PALO's strong selective binding affinity to the 5-HT 3 receptors and its longer half-life [7] [8] [9] . PALO is a widely used 5-HT 3 RA, and the combination therapy of PALO on day 1 and DEX for 1 to 3 days [10] is a suggested combination by all guidelines for the prevention of CINV induced by moderate-emetogenic chemotherapy (MEC) [1, 6, 7, [11] [12] [13] [14] [15] . However, this combination provides suboptimal control for CINV induced by highly emetogenic chemotherapy (HEC). Hence, guidelines advise the addition of olanzapine or a neurokinin-receptor 1 antagonist (NK-1-RA; aprepitant, fosaprepitant, netupitant, rolapitant) as third agent [14, 16] .
A recent network meta-analysis showed that NK-1-RAbased triple regimens were equivalent in controlling CINV regardless of dexamethasone dose or the 5-HT 3 RA agent used, indicating a class rather than an agent-specific effect [17] . A related meta-analysis demonstrated better CINV prevention in the overall and delayed phases with an olanzapinebased triple regimen rather than NK-1-RA-based triple regimens [18] . Despite these treatment options, high cost, availability, side-effects, and low adherence to treatment guidelines are significant challenges in achieving complete control of CINV and underscore the need for novel treatment options [11] [12] [13] [19] [20] [21] [22] [23] . The recent meta-analyses [17, 18] did not include a 2017 randomized controlled trial of the thalidomide and palonosetron + dexamethasone (PALO-DEX) triplet that reported significant improvements in CINV induced by HEC compared with PALO-DEX alone. This regimen has not been compared with other regimens and has not been integrated into guidelines [13] . Thus, we conducted a Bayesian network meta-analysis to compare the efficacy of olanzapine-, NK-1-RA-, and thalidomide-based triple regimens to PALO-DEX in preventing CINV induced by HEC.
Methods
Reporting of this network meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and extension statement for network meta-analyses [19] .
Data collection
We searched PubMed, MedLine Ovid, Embase, and Clinicaltrials.gov from inception through 22 Mar 2018. We specified our search using the patients, intervention, comparator, outcome, and study design (PICOS) strategy for clinical evidence of olanzapine, NK-1-RA, or thalidomide in combination with PALO-DEX in controlling CINV induced by HEC (Table 1) . We reviewed the references of relevant articles and prior systematic reviews and meta-analyses.
Outcome measures
The primary outcome was complete response (CR), which refers to no emesis nor use of rescue medications. The secondary outcome was the rate of no nausea (RNN). Both outcomes were measured in the acute (0-24 h), delayed (25-120 h), and overall phases (0-120 h) post-chemotherapy.
Inclusion and exclusion criteria
We included English-language randomized controlled trials assessing the efficacy of olanzapine, NK-1-RA, or thalidomide in combination with PALO-DEX in controlling CINV induced by HEC in patients 18 years or older and reporting CR and/or RNN as the efficacy outcomes. To minimize variation among studies in our analyses, we only included studies with the backbone of PALO-DEX as part of the regimens studied. This is predicated on preclinical data indicating that PALO is effective in antagonizing 5-HT 3 receptors at allosteric binding sites, inhibiting indirectly NK-1 receptors' natural ligands (substance P), and exhibiting an in vitro synergistic effect when combined with netupitant [8, 9] .
Data extraction, risk of bias, and quality assessment Two investigators (EC and AS) independently reviewed titles and abstracts of publications produced; retrieved full papers of studies possibly eligible for inclusion; and adjudicated papers as to meeting inclusion criteria. Data were extracted using a pre-specified worksheet. The Cochrane risk-of-bias tool was used to assess the quality of studies.
Statistical analysis
We used the Bayesian network meta-analysis software WinBUGS v.1.4.3 (MRC Biostatistics Unit, Cambridge, UK) to compare all treatments with each other. CR and RNN were expressed as odds ratios (OR) and 95% credible interval (95% Crl) for the acute, delayed, and overall phases. ORs were estimated for each treatment comparison by running 20,000 iterations of which the first 10,000 iterations in the model were used as burn-in. The binomial likelihood and non-informative priori were used in the analysis. The convergence of the model was assessed based on the trace plots and Brooks-Gelman-Rubin statistic. Random-effects models were applied due to the assumed heterogeneity among the included studies and to ensure the generalizability of the results. Ranking probabilities of treatments were calculated using the surface under the cumulative ranking curve (SUCRA) to identify the probability of one treatment as best option against the worst option. We performed sensitivity analyses using informative priors based on empirical evidence of Turner et al. [20] .
Results
The search yielded 751 articles (Fig. 1 ). Of these, 52 duplicate articles were removed, and an additional 631 articles were excluded based on the inclusion and exclusion criteria. The full texts of the remaining 68 articles were reviewed. Of these, 40 articles were observational studies or case reports, 6 articles did not report CR and/or RNN, 12 articles reported on different interventions, and 1 article was a study protocol. We retained 9 studies involving 2859 patients that assessed the efficacy, expressed as CR and/or RNN, of adding olanzapine, NK-1-RA or thalidomide as third agent to PALO-DEX in patients prone to CINV after 1 cycle of HEC (Table 2) [11 -13, 21-26] .
Characteristics of studies
Three studies investigated NK-1-RA-based triple regimens. PALO was administered as 0.5 mg orally in two studies and as 0.25 mg IV in one study. Also, DEX was given on day 1 only in one study, while it was given for 4 days in two studies [11, 21, 22] .
Olanzapine-based triple regimens were studied in five RCTs, including four comparing these regimens with NK-1-RA-based triple regimens and one comparing them with PALO-DEX [12, [23] [24] [25] [26] . In four studies, 10 mg of olanzapine was administered orally for a minimum of 4 days, while a regimen of 10 mg on day 1 followed by 5 mg on days 2 to 4 was used in the 5th study. A thalidomide-based triple regimen was studied in one RCT comparing it with PALO-DEX, which was administered with same dose and duration in both study arms [13] .
The network plot of studies ( Fig. 2) represents each intervention as a circled node. The node's circumference reflects the number of subjects studied. The lines connecting the nodes represent direct comparisons and their thickness indicates the number of studies included in each comparison.
Study quality
Only five of the nine studies reported allocation concealment, and four studies were unclear on this methodology element (Figs. S1 and S2). Only four studies used double blinding.
Comparative efficacy of olanzapine, NK-1-RA, and thalidomide
In terms of CR (Table 3) , the olanzapine-based triple regimen showed significantly greater benefit in the acute, delayed, and overall phases versus the PALO-DEX regimen (OR = 3.97, 95% credible interval (95% CrI) = 1.02-19.13; OR = 5.62, 95% CrI = 1.66-28.58; OR = 4.79, 95% CrI = 1.40-24.02, respectively). The NK-1-RA-based regimen showed a significantly greater benefit in the delayed and overall phases versus the PALO-DEX regimen (OR = 5.62, 95% CrI = 1.66-28.58; OR = 4.79, 95% CrI = 1.40-24.02, respectively). No differential benefit in CR was detected between the olanzapine-, NK-1-RA-, and thalidomide-based regimens in either of the three phases. The SUCRA probabilities ranked the onlanzapinebased regimen as the best treatment option in the acute, delayed, and overall phases (82, 78, and 75%, respectively) and the NK-1-RA-based regimen as the second best option (65.6, 62, and 64.2%, respectively) (Table S1 ).
In terms of RNN (Table 4) , the olanzapine-based regimen showed significantly greater benefit than the NK-1-RA-based and the PALO-DEX regimens in the delayed phase only (OR = 2.90, 95% CrI = 1.34-5.15; OR = 4.53, 95% CrI = 1.89-10.55, respectively). The SUCRA probabilities ranked the olanzapine-based regimen as the best option in the acute, delayed, and overall phases (63.3, 93, and 83.5%, respectively) while ranking the NK-1-RA-based regimens as the second best option in the acute and overall phases only (53.8 and 43%, respectively) (Table S2 ). Sensitivity analyses of CR and RNN outcomes in the acute, delayed, and overall phases using informative priors were similar to the primary analyses (Tables S3 and S4) . Fig. 1 Search strategy: study selection process using preferred reporting items for systematic reviews and meta-analyses (PRISMA) 
Discussion
This Bayesian network meta-analysis comparing the prophylactic efficacy of olanzapine, NK-1-RA, and thalidomide added as third agents with PALO-DEX in preventing CINV in patients receiving HEC yielded several important findings. First, the olanzapine-based triple regimens consistently showed better prophylactic efficacy than the recently tested thalidomide-based triple regimen. By including this newly proposed regimen, our analysis extends the systematic review of phases I and II trials [27] and the meta-analysis of RCTs [18] of olanzapine-based triple regimens, as well as the metaanalysis of NK-1-RA-based triple regimens [17] . Second, our meta-analysis confirms the meta-analysis demonstrating better CINV prevention with olanzapine-based triple regimens versus NK-1-RA-based triple regimens [18] . Third, the recently tested thalidomide-based triple regimen did not offer an incremental prophylactic benefit over other triple regimens. Lastly, the SUCRA probability ranking sfor the NK-1-RAbased and the thalidomide-based regimens were inconsistent across phases in terms of CR and did not indicate one regimen having an advantage over the other in terms of RNN. Our findings have been reported using the random-effect model due to the presumed heterogeneity among the included studies and to assure generalizability-two reasons why a fixed-effect analyses was not indicated. We included only studies with the backbone of PALO-DEX as part of the regimens and used the random-effects analysis to manage any variability in effect size across studies.
As the NCCN guidelines indicate [14] , there is an agreement on using dexamethasone as a main component of a triple regimen. However, there is a paucity of clinical research data about which 5-HT 3 RA to add. Furthermore, the NCCN guidelines do not recommend PALO as the preferred 5-HT 3 RA to be combined with NK-1-RA. Similarly, the recent MASCC-ESMO guideline does not suggest PALO as the universally [16] . However, PALO has some advantages over older 5-HT 3 RAs, even if less according to recent analyses [28] . Despite newly approved, effective novel antiemetic agents endorsed in evidence-based guidelines, the lack of adherence to these guidelines remains a major obstacle to achieving CINV control in daily clinical practice [29] . This is further compounded by side-effects and adverse drug reactions associated with selected agents, such as the recent FDA warnings against intravenous rolapitant regarding anaphylaxis and the subsequent removal of this formulation from the market [30] . In addition, olanzapine is a typical antipsychotic that binds non-selectively on multiple receptors involved with CINV such as dopamine, serotonin, histamine, as well as, more generally, adrenergic and muscarinic receptors [1, 12, 14, 18] . This non-selectivity of olanzapine is associated with drowsiness, fatigue, and sleep disturbances, is poorly tolerated by patients, and often requires dose lowering. Lastly, high cost and issues with drug availability in developing countries remain to be challenges in providing complete control of CINV to patients [31, 32] . Future clinical trials should focus on the optimal third agent to be added to the PALO-DEX backbone in terms of safety, efficacy, tolerance, and economic value.
Conclusion
Based on the data from our network meta-analysis, there is insufficient evidence to support adding thalidomide or the class of NK-1 antagonists as third agents to a PALO-DEX backbone regimen to prevent CINV induced by HEC. Our analyses revealed significant signals that the olanzapinebased triple regimen prevailed in terms of CR and RNN. The side-effects of olanzapine and the absence of direct comparisons explain why some guidelines are cautious in suggesting the use of this agent.
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